業績・学会発表

研究業績

英文原著論文

  1. Xu L, Nagata N, Ota T. Glucoraphanin: A broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance. Adipocyte 2018 Jun 14. doi: 10.1080/21623945.2018.1474669.
  2. Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M. Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition. Oncotarget 9:16400-16417, 2018
  3. Shima KR, Ota T, Kato K, Takeshita Y, Misu H, Kaneko S, Takamura T. Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in type 2 diabetes and chronic liver disease patients: A pilot randomised controlled and add-on study. BMJ Open Diabetes Res Care doi:10.1136/bmjdrc-2017-000469 2018
  4. Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Kamei J, Ishikawa H, Komatsu Y, Kaneko S, Ota T. A porcine placental extract prevents steatohepatitis by suppressing activation of macrophages and stellate cells in mice. Oncotarget 9:15047-15060, 2018
  5. Ni Y, Wu T, Yang L, Xu Y, Ota T, Fu Z. Protective effects of astaxanthin on a combination of D-galactose and jet lag-induced aging model in mice. Endocr J 2018 Mar 10. doi: 10.1507/endocrj.EJ17-0500
  6. Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte Dec 11:1-8, .doi: 10.1080/21623945.2017.1413516.2017
  7. Funaki M, Kitabayashi J, Shimakami T, Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko, S. Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep 7:16978, 2017
  8. Ota T. Immune regulation of glucose and lipid metabolism. Diabetol Int. 8:257-267, 2017
  9. Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Mayoux E, Kaneko S, Ota T. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet‒induced Obese Mice. EBioMedicine. 20:137‒149, 2017
  10. Pongkan W, Takatori O, Ni Y, Xu L, Nagata N, Chattipakorn SC, Usui S, Kaneko S, Takamura M, Sugiura M, Chattipakorn N, Ota T. β-Cryptoxanthin exerts greater cardioprotective effects on cardiac ischemia-reperfusion injury than astaxanthin by attenuating mitochondrial dysfunction in mice. Mol Nutr Food Res. 61(10). doi: 10.1002/mnfr.201601077, 2017
  11. Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients. 9,387,2017
  12. Kobori M, Takahashi Y, Sakurai M, Ni Y, Chen G, Nagashimada M, Kaneko S, Ota T. Hepatic Transcriptome Profiles of Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E. Int. J. Mol. Sci. 18(3), E593, 2017
  13. Nagata N, Xu L, Kohno S, Ushida Y, Aoki Y, Umeda R, Fuke N, Zhuge F, Ni Y, Nagashimada M, Takahashi C, Suganuma H, Kaneko S, Ota T: Glucoraphanin Ameliorates Obesity and Insulin Resistance Through Adipose Tissue Browning and Reduction of Metabolic Endotoxemia in Mice. Diabetes. 66(5):1222-1236, 2017.
  14. Takeda Y, Fujita Y, Yanagimachi T, Honjo J, Abiko A, Asai M, Haneda M. Prediabetes Exhibits Decreased Disposition Index Correlated with Deterioration of Glycemic Parameters in Nonobese Japanese Subjects: A Cross-Sectional Study from Medical Examination. Metab Syndr Relat Disord. 15(6):296-303, 2017
  15. Takeda Y, Fujita Y, Sakai K, Abe T, Nakamura T, Yanagimachi T, Sakagami H, Honjo J, Abiko A, Makino Y, Haneda M. Expression of transcription factors in MEN1-associated pancreatic neuroendocrine tumors. Endocrinol Diabetes Metab Case Rep. 2017 Sep 4;2017. pii: 17-0088
  16. Hiroaki Haga, Irene K Yan, Kenji Takahashi, Akiko Matsuda, Tushar Patel. Extracellular vesicles from bone marrow derived mesenchymal stem cells improve survival from lethal hepatic failure in mice. Stem Cells Trans Med. 2017 Apr6(4):1262-1272.

英文著書

  1. Ota T:Chapter 7:Diabetes and Liver Disorders. In Diabetes and Aging -related Complications, Springer Nature, 85-99, 2018 DOI 10.1007/978-981-10-4376-5

邦文原著論文

  1. 玉木陽穂,太田嗣人:NASH/NAFLDの新知見,インスリン抵抗性改善化合物 肝胆膵 76:751-757,2018
  2. 長田直人 太田嗣人:スルフォラファンの肥満抑制効果 BIO INDUSTRY BIO INDUSTRY 35(2):15-23,2018 シーエムシー出版
  3. 太田嗣人:免疫応答制御による糖脂質代謝調節機構の研究 糖尿病 60(10):694∼696,2017
  4. 太田嗣人:肝臓における慢性炎症と糖尿病、臓器炎症からみた糖尿病および糖尿病性合併症 糖尿病診療マスター15(10):873-878,2017 医学書院
  5. 太田嗣人:NASH/NAFLDに対する新規糖尿病治療薬の効果と可能性 質疑応答プロからプロへ 日本医事新報4882:59-59,2017日本医事新報社
  6. 太田嗣人:非アルコール性脂肪肝(NAFLD)と脂質代謝異常、肝疾患と脂質代謝異常 The Lipid 28(2):51-56, 2017 メディカルレビュー社
  7. 麻生 和信:肝癌診断における造影3D超音波の新展開 造影Smart 3Dの有用性. 映像情報Medical49(5) Page43-47(2017,05)
  8. 麻生 和信, 岡田 充巧, 玉木 陽穂, 太田 雄, 大竹 晋, 鈴木 裕子, 岩本 英孝, 高橋 賢治, 山北 圭介, 北野 陽平, 和田 佳緒利, 石田 歩, 野邉 浩枝, 嶺 喜隆:肝癌診断における造影3D超音波の有用性. Rad Fan 15(5) Page61-63(2017,04)